Entrepreneur UK's London 100: Loan Tube
For too long, the UK lending market has been riddled with confusion, hidden fees and unfair lending practices.
LoanTube is the UK's first loan comparison marketplace where consumers receive real, pre-qualified unsecured loan offers.
There are no misleading teaser rates and no bait-and-switch tactics, ensuring borrowers have complete clarity, choice and control over their financial decisions.
Today, LoanTube processes over 300,000 loan applications every month and works with over 30 FCA-regulated lenders.
Looking ahead, LoanTube is pioneering AI-driven lending solutions and expanding into embedded finance, ensuring a future where borrowing is seamless, transparent and even more accessible.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 hours ago
- Business Wire
Artera Receives U.S. FDA De Novo Marketing Authorization for AI-Digital Pathology Software Revolutionizing Prostate Cancer Care
SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today that the U.S. Food and Drug Administration (FDA) has granted De Novo authorization for ArteraAI Prostate, establishing it as the first and only AI-powered software authorized to prognosticate long-term outcomes for patients with non-metastatic prostate cancer. ArteraAI Prostate is now recognized as an FDA-regulated Software as a Medical Device (SaMD). The technology's De Novo authorization establishes a new product code category for future AI-powered digital pathology risk-stratification tools, and enables its implementation at the point of diagnosis at qualified pathology labs in the U.S. This capability addresses a critical gap in prostate cancer care by reducing delays in delivering actionable insights at diagnosis, helping clinicians and patients make informed treatment decisions with greater confidence. 'This is a defining moment for AI in cancer care,' said Andre Esteva, CEO and co-founder of Artera. 'The FDA's decision validates the power of our MMAI platform to deliver on our vision to create AI-guided tools that enable data-backed and tailored treatments for each patient, leading to more confidence throughout the cancer journey, and ultimately, save more lives.' 'This approval highlights the groundswell of excitement surrounding the incorporation of AI into clinical practice flows. We need to utilize deep learning AI models to augment and better refine what a pathologist is able to report and Artera is leading the charge,' said Dr. Adam Cole, Founder and CSO at TruCore Pathology Group. 'As the demand for pathology services continues to outpace available capacity, tools like ArteraAI Prostate are critical. Implementing this software enhances our ability to deliver personalized insights more quickly, improves workflow efficiency, and allows us to scale services while increasing the quality of care.' Earning FDA De Novo authorization is a rare achievement, designed for novel medical innovations. This accomplishment marks yet another milestone for Artera, spotlighting its leadership and unwavering commitment to scientific rigor and excellence. Notably, the FDA authorization includes a Predetermined Change Control Plan, granting Artera the ability to expand platform capabilities through validating compatibility with additional digital pathology scanners without requiring further 510(k) submissions. The De Novo authorization for ArteraAI Prostate follows its earlier Breakthrough Device Designation. While the De Novo authorization applies specifically to the ArteraAI Prostate medical device software, Artera's underlying MMAI platform is also commercially available through the ArteraAI Prostate Test, as a Laboratory Developed Test (LDT). With this milestone, Artera continues to expand its pipeline of MMAI-powered software to support personalized cancer care. To learn more, visit About Artera Artera is a global leader in precision medicine, leveraging multimodal artificial intelligence (MMAI) to personalize cancer care. Artera's MMAI platform leverages a patient's digitized biopsy images along with the patient's clinical data to determine cancer aggressiveness and predict therapy benefit. This approach has been validated in multiple Phase 3 randomized trials, across different cancers, and is available in multiple versions across the globe. Artera's flagship product, the ArteraAI Prostate Test, is commercially available as a laboratory-developed test in the US and internationally through its distribution partners. The ArteraAI Prostate Test is the first of its kind to deliver both prognostic and predictive insights for patients with prostate cancer, empowering clinicians and patients to make more informed treatment decisions. Additional MMAI-powered products include the ArteraAI Breast Test (UKCA), the ArteraAI Prostate Biopsy Assay (UKCA), and ArteraAI Prostate (FDA). Artera has regulatory authorization for its medical device product in the US and UK. Artera's headquarters is based in Los Altos, California, while its CLIA-certified and clinical laboratory is located in Jacksonville, Florida. For more information about Artera, visit
Yahoo
a day ago
- Yahoo
Paxos is applying to become a US bank — Here's why that matters
Paxos, the company that issues PayPal's $1 billion stablecoin, has applied for a national trust bank charter in the US, becoming the latest crypto company to pursue becoming a Federally-regulated bank in the US. It's a move that could give Paxos a gloss of establishment respectability, and a direct presence in America's financial sector. If approved, Paxos will be able to operate across the US without navigating the patchwork of local banking licences. However, while an approval would allow Paxos to hold customer assets and settle transactions, it won't act as a traditional lender that can accept deposits and issue loans. Paxos' charter application comes at a time when Washington, under the Trump administration, has warmed up to crypto. In July, President Donald Trump signed the Genius Act into law, effectively legalising stablecoins in the US. Circle and Ripple Paxos is the latest crypto company to pursue banking charter status. Circle and Ripple both applied earlier this summer. Chris Colson, payments guru at the Atlanta Federal Reserve, told DL News that an approval would enhance trust in their respective stablecoins. 'It potentially paves the way for broader institutional and cross-border adoption,' he said. Yet, those US banking charter ambitions rely on the hope that the regulatory thaw has extended to the US Treasury Department's Office of the Comptroller of the Currency, the agency that licenses and supervises all national banks. An OCC charter has been a tough nut to crack for crypto companies. Only one firm, Anchorage Digital, has been able to scale the process. Paxos itself tried to obtain a national bank charter in 2020 but its application stalled and expired in 2023. Earlier in August, the stablecoin issuer settled with the New York Department of Financial Services for $26.5 million over its alleged failure to conduct due diligence on Binance. Paxos was the issuer behind Binance's BUSD stablecoin, which once peaked at $23 billion in market value. Crypto market movers Bitcoin is down 1.4% over the past 24 hours and is trading at $118,433. Ethereum is up 2.6% in the same period to $4,295. What we're reading Trump Media brings Truth token plans into the open in latest SEC filing — DL News White House Crypto Advisor Bo Hines Steps Down — Unchained Do Kwon May Plead Guilty in US Case Over $40 Billion Terraform Collapse — Bloomberg Ether Breaks $4,000 as Spot ETFs Get Massive Inflows — Unchained Crypto law bonanza raises concerns around whether agency staff can regulate groundswell — DL News Osato Avan-Nomayo is our Nigeria-based DeFi correspondent. He covers DeFi and tech. Got a tip? Please contact him at osato@ — DL News Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
a day ago
- Yahoo
Lucasys Recognized Again on Inc. 5000 List of America's Fastest-Growing Private Companies
ATLANTA, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Inc. revealed today that Lucasys, the leading provider of tax technology and technology-enabled services for regulated utilities, has been named once again to the annual Inc. 5000 list for 2025, the most prestigious ranking of the fastest-growing private companies in America. The list provides a data-driven snapshot of the most successful companies within the economy's most dynamic segment—its independent, entrepreneurial businesses. Past honorees include companies such as Microsoft, Meta, Chobani, Under Armour, Timberland, Oracle, and Patagonia. 'The Lucasys team is excited to be recognized again as one of America's fastest-growing companies. Lucasys' best-in-class software solutions and technology-enabled services have been adopted by over twenty leading energy and utility companies in North America, and the marketplace momentum is significant. Being named to the Inc. 5000 is a testament to the incredible success of our customers and industry-leading solutions delivered by our team. With the recent addition of Tax Provision to the Lucasys Income Tax Suite, we look forward to building on the momentum, delivering fast, reliable, and cost-effective solutions to more of North America's top enterprises.'-Vadim Lantukh, Co-founder and CEO of Lucasys This year's Inc. 5000 honorees have demonstrated exceptional growth while navigating economic uncertainty, inflationary pressure, and a fluctuating labor market. Among the top 500 companies on the list, the median three-year revenue growth rate reached 1,552 percent, and those companies have collectively added more than 48,678 jobs to the U.S. economy over the past three years. For the full list, company profiles, and a searchable database by industry and location, visit: 'Making the Inc. 5000 is always a remarkable achievement, but earning a spot this year speaks volumes about a company's tenacity and clarity of vision. These businesses have thrived amid rising costs, shifting global dynamics, and constant change. They didn't just weather the storm—they grew through it, and their stories are a powerful reminder that the entrepreneurial spirit is the engine of the U.S. economy.' -Mike Hofman, Editor-in-Chief of Inc. Lucasys' inclusion on the Inc. 5000 list comes at a time of growth for the company, which experienced tremendous growth from 2021 to 2024. Through its solutions, Lucasys has empowered businesses to streamline accounting and tax operations, adopt modern software solutions, and build internal expertise in mission-critical accounting and tax functions. Lucasys continues to accelerate on its mission to deliver fast, reliable, and cost-efficient solutions for North American energy and utility companies. Companies on the 2025 Inc. 5000 are ranked according to percentage revenue growth from 2021 to 2024. To qualify, companies must be U.S.-based, privately held, for-profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2024. (Since then, some on the list may have gone public or been acquired.) About Lucasys Lucasys delivers software and technology-enabled services to empower finance, accounting, and tax professionals in asset-intensive industries to optimize the financial performance of their fixed assets and proactively meet changing regulatory and compliance requirements. With a core focus on rate-regulated utilities and energy companies, Lucasys provides the industry and domain expertise these organizations require to meet their business objectives. To learn more about Lucasys, visit or follow the company on LinkedIn. About Inc. Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating the future of business. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit LucasysContact: Tommy Ferguson, CMO, Lucasys1-844-582-2797contact@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
